Proteomics · Orbitrap LC-MS/MS · DDA · DIA · TMT · PRM

Quantify the functional layer of biology.

Proteins execute the programmes your genomics predicts. Orbitrap LC-MS/MS identifies and quantifies thousands of proteins per sample, for biomarker discovery, mechanism, PTM mapping and biopharma characterisation. Mass spectrometry runs at our partner laboratory; study design, data analysis and reporting are done by our team in Hyderabad.

4
quantitation modes: DDA · DIA · TMT · PRM
1%
FDR at PSM level
3
PTM workflows: phospho · ubiquitin · acetyl
GO + KEGG
functional enrichment

Proteomics Services at Nucleome Informatics

LC-MS/MS runs on Thermo Scientific Orbitrap high-resolution mass spectrometers with nano/UHPLC separation at our partner laboratory. Nucleome designs the study, coordinates sample QC and shipping, and carries out the full data analysis and reporting in-house.

We cover the standard quantitative workflows: DDA discovery, DIA cohort quantitation, TMT multiplexing, targeted PRM, and phospho-, ubiquitin- and acetyl-PTM enrichment. Abundance tables are where the biology starts, so every project goes through our analysis pipeline, from raw protein abundance tables to functional interpretation.

  • Raw data plus processed protein and peptide quantitation tables at 1% FDR (PSM level)
  • Differential abundance analysis with multiple-testing correction
  • PTM site localisation, scored by localisation probability, for phospho, acetyl and ubiquitin workflows
  • Gene Ontology and pathway enrichment on protein lists
  • QC documentation: standard digest performance, peptide and protein IDs, quantitative CVs
  • A written analysis report with search parameters, database versions and interpretation notes

The analysis pipeline (included with every project)

  • Import and harmonisation: protein abundance tables, with QC of identification frequency, sample coverage and reproducibility.
  • Variance-stabilising normalisation (VSN): calibrates samples so variation is comparable across intensity ranges.
  • MNAR-appropriate imputation (MinProb-class): missing values in label-free data concentrate at low intensity (missing-not-at-random), so imputation is chosen accordingly.
  • Differential testing on a limma framework: borrows information across proteins to stabilise variance in small experiments.
  • Visualisation: PCA, correlation analysis, volcano plots and heatmaps.
  • Functional enrichment: GO (biological process, cellular component, molecular function) and KEGG pathways.
  • Honest identification control: 1% FDR by decoy-database search, with protein groups reported where shared peptides make inference ambiguous.
Already have data? If you already hold label-free protein abundance tables from another lab or instrument, our data-analysis-only service runs them through the same DEP/limma pipeline. See Bioinformatics services. Raw data must be supplied by you or generated through Nucleome.

From first principles to expert-level analysis

New here? Start with Foundations. Planning a study or reviewing results? Jump to Practitioner or Expert. Each level builds on the one before it, so you can read this page as a short course or dip in where you need to.

Start here if you are new to this service: six ideas that explain what it is and why it matters.

Level 1

What is proteomics?

The systematic measurement of proteins in a sample: their identity, abundance and modifications. Proteins carry out the programmes encoded in the genome, so proteomics shows what the genome is actually doing.

Level 1

What is an Orbitrap?

A high-resolution mass spectrometer that measures peptide masses very accurately, which makes it possible to identify thousands of proteins per run with confidence.

Level 1

What is LC-MS/MS?

Liquid chromatography separates peptides; the mass spectrometer measures them and fragments them (MS/MS) to read their sequence. Together they identify and quantify proteins.

Level 1

DDA vs DIA: which do I need?

DDA maximises identification depth for discovery; DIA gives more reproducible quantitation across many samples. Cohort studies usually favour DIA; mechanism and discovery projects often start with DDA.

Level 1

What samples can I analyse?

Cells, tissues, plasma or serum, immunoprecipitates, secretomes, and plant or microbial samples, with preparation matched to the sample type.

Level 1

What will I get?

Protein and peptide quantitation tables with FDR statistics, differential analysis, pathway enrichment and a written report, plus the raw data.

For researchers planning a study: the design choices that shape your results.

Level 2

Choosing a quantitation mode

Few samples and a discovery question: DDA or TMT. Larger cohorts: DIA. A short list of candidate proteins to confirm: targeted PRM. We recommend the mode at the design call.

Level 2

Replicates

Plan at least three biological replicates per group. Clinical and plasma studies need more, because biological variation between people is larger than technical variation.

Level 2

Plasma and serum

A few abundant proteins such as albumin and immunoglobulins dominate the signal. Depletion or fractionation increases depth, at the cost of throughput and cost per sample.

Level 2

PTM studies

Modified peptides are rare, so PTM work needs more starting material and an enrichment step. Collect samples with protease and phosphatase inhibitors and process them quickly.

Level 2

TMT designs

Isobaric tags let several samples run together in one multiplex. A pooled reference channel links multiplexes; ratio compression is expected with TMT and is reported.

Level 2

Reading the results

Check QC first: proteins identified per sample, missing values and CVs. Then read the protein groups, fold changes and adjusted p-values in the differential table.

For bioinformaticians and specialists: what happens under the hood, and the terms used in our reports.

Level 3

False discovery control

Spectra are searched against target and decoy databases, and identifications are filtered at 1% FDR. Proteins sharing peptides are reported as protein groups, not single names.

Level 3

DIA analysis

DIA data are analysed library-free or against a spectral library. Per-run completeness is reported alongside quantitation so you can see where values are missing.

Level 3

Missing values

In label-free data, values are mostly missing because a protein fell below detection (MNAR). MinProb-class imputation reflects that, and results are checked for sensitivity to the choice.

Level 3

Normalisation and batches

VSN makes variance comparable across intensities. Randomised run order and QC standards keep batch effects measurable and correctable.

Level 3

PTM site localisation

Each modification site carries a localisation probability. Site-level changes are interpreted alongside protein-level abundance, so a change in the protein is not mistaken for a change in modification.

Level 3

Multi-omics integration

Protein results can be linked to transcriptomic, metabolomic and genomic data from the same samples through our OmniIntegrate pipeline.

PSM
Peptide-spectrum match: one MS/MS spectrum assigned to one peptide sequence.
FDR
False discovery rate: the expected share of incorrect identifications, estimated with decoy sequences.
DDA
Data-dependent acquisition: the instrument picks the most intense peptides to fragment.
DIA
Data-independent acquisition: all peptides in set mass windows are fragmented, run after run.
TMT
Tandem mass tags: isobaric labels that let several samples be measured together.
PRM
Parallel reaction monitoring: targeted, high-resolution quantitation of chosen peptides.

What to send us

Typical starting requirements per sample type. Final requirements are confirmed at project intake and depend on the workflow and sample; these amounts are starting points, not strict minimums.

Sample typeTypical amountNotes
Cell pellets1–5 × 10⁶ cellsWash with PBS to remove media proteins
Tissue10–50 mgSnap-frozen; for PTM work, rapid handling with inhibitors
Plasma / serum10–50 µLDepletion and/or fractionation advised for depth
Immunoprecipitates10–100 µg proteinInclude matched controls for interactomics
Secretome / conditioned media5–10 mLSerum-free conditioning window before collection
Handling and shipping. Store at −80 °C, ship on dry ice and avoid freeze–thaw cycles. Use MS-compatible lysis buffers (minimise SDS where possible); keratin contamination control matters for low-input samples. For PTM workflows, add protease and phosphatase inhibitors at collection and process rapidly. We coordinate shipping to the partner laboratory.

How the service works, step by step

Orbitrap-based LC-MS/MS is the established platform for deep proteome profiling, and FDR-based identification control and DIA quantitation are established practice in the proteomics literature. See the references below.

Figure 1Quantitation modes compared.Schematic
DDA discoveryDIA cohortsMaximum identification depthSome values missing across runsBest for mechanism and discovery studiesReproducible quantitation at scaleLibrary-free or library-basedPer-run completeness reported
Figure 1 | Quantitation modes compared. DDA suits discovery; DIA suits cohorts. (Illustrative schematic, not sample data.)
Figure 2Workflow.Schematic
Extraction & digestionMatched to sample typePTM enrichmentOptionalNano/UHPLC separationPartner laboratoryOrbitrap MS/MSDDA · DIA · TMT · PRMDatabase search1% FDRQuantitation & reportAnalysis by Nucleome
Figure 2 | Workflow. From sample to quantified, annotated protein lists and a written report. (Illustrative schematic, not sample data.)

Why Orbitrap LC-MS/MS?

  • Speed and sensitivity: high-resolution Orbitrap analysers with fast MS/MS duty cycles maximise peptide identification depth per unit time.
  • Quantitative flexibility: one platform supports label-free, DIA, TMT and PRM, matched to cohort size and question.
  • PTM capability: high mass accuracy and HCD fragmentation enable confident PTM site localisation.

Built for the questions you are asking

The platforms, pipelines and standards behind this service.

Thermo Orbitrap HRMS

High-resolution, high-mass-accuracy analysis with fast duty cycles at our partner laboratory: the backbone of deep proteome coverage.

Nano/UHPLC separation

Nano-flow and micro/UHPLC methods matched to sample amount and complexity, from cell lysates to plasma.

DDA discovery

Data-dependent acquisition for maximum identification depth in discovery experiments.

DIA quantitation

Data-independent acquisition for reproducible quantitation across large cohorts, library-free or library-based, with per-run completeness reported.

TMT multiplexing

Isobaric tagging for multiplexed relative quantitation, with internal referencing across conditions.

Targeted PRM

High-resolution targeted quantitation for candidate validation and defined protein panels.

What you receive

Every project ships with the complete deliverable set: data, analysis and documentation.

  • Raw data files with full acquisition parameters
  • Protein and peptide quantitation tables at 1% FDR (PSM level)
  • Differential abundance analysis with adjusted p-values and fold changes
  • PTM site tables with localisation probabilities (PTM workflows)
  • GO and KEGG functional enrichment on protein lists
  • QC documentation (standard digest performance, quantitative CVs) and a written methods report

Data analysis in pictures

Illustrative analyses showing what your project report contains. All data below are simulated for illustration, not client results.

Example 1Discovery proteomics: differential abundance.Simulated
-2-101201234log2 fold change (treated / control)−log10 (adjusted p)Up in treated (26)Down in treated (35)
Volcano plot of protein-level differential abundance between treated and control cells (simulated data, 1% FDR at PSM level). Grey points pass neither threshold; coloured points are reported with fold change, adjusted p-value and gene name in the deliverable table. (Simulated data, not client results.)
Example 2DIA vs DDA quantitative reproducibility.Simulated
010203040506020% CVDIA (median CV ~9%)DDA (median CV ~17%)Protein quantitative CV across cohort (%)Density
Distribution of protein CVs across a simulated cohort. DIA (median CV ~9%) is tighter than DDA (median CV ~17%), which is why cohort studies are usually run in DIA. The dashed line marks a common 20% CV threshold. (Simulated data, not client results.)

What this service does and does not cover

Scope note. LC-MS/MS acquisition is performed at our partner laboratory; study design, sample QC coordination, data analysis and reporting are performed by Nucleome. Proteomics depth is bounded by sample dynamic range (most severely in plasma), instrument time and database completeness, and we state the expected depth for your sample type before you commit. DDA missingness, TMT ratio compression and PTM stoichiometry limits are reported, not hidden. Protein identifications depend on the reference database for the organism; non-model organisms need custom databases. Turnaround times and pricing are set per project.

Service highlights

What you can expect from our team in Hyderabad.

Orbitrap HRMS through our partner lab

Thermo Orbitrap high-resolution MS with nano/UHPLC, discovery and quantitation on one platform, with Nucleome managing the project end to end.

Full quantitation menu

DDA, DIA, TMT and PRM, matched to your cohort size and question.

1% FDR discipline

Identification control at PSM level, with search parameters and database versions reported.

PTM expertise

Phospho-, ubiquitin- and acetyl-proteomics with localisation-probability scoring.

Analysis in-house

Every dataset goes through our own pipeline and is reported by our scientists in Hyderabad.

Multi-omics ready

Integration with transcriptomics, metabolomics and genomics through our Bioinformatics service (OmniIntegrate).

Frequently asked, in plain language

From the basics to the finer points of design and interpretation.

BasicWhat is the difference between DDA and DIA?
DDA fragments the most intense peptides it sees, which maximises identifications in discovery work but leaves some values missing between runs. DIA fragments everything in set mass windows, giving more complete and reproducible quantitation across many samples.
BasicWhat samples do you accept?
Cell pellets, tissue, plasma or serum, immunoprecipitates, secretomes, and plant or microbial material. See the sample table above for typical amounts; final requirements are confirmed at intake.
BasicHow many proteins can you identify?
It depends mainly on the sample. Cell lines and tissues typically yield several thousand protein groups; undepleted plasma yields far fewer because a handful of abundant proteins dominate. We state the expected depth for your sample type before you commit.
IntermediateCan you quantify proteins absolutely?
Discovery workflows give relative quantitation between samples. For absolute amounts of selected proteins, targeted PRM with labelled reference peptides is the usual route; we can scope this with you.
IntermediateDo you do PTM studies?
Yes: phospho-, ubiquitin- and acetyl-proteomics, with an enrichment step and site localisation probabilities. These studies need more starting material and careful collection with inhibitors.
IntermediateHow do you control false discoveries?
Identifications are filtered at 1% FDR using a target–decoy database search, and differential results use multiple-testing-corrected p-values. Proteins that share peptides are reported as protein groups.
AdvancedCan you handle plasma biomarker discovery?
Yes, with realistic expectations: plasma has a very wide dynamic range. Depletion or fractionation and a DIA design with enough samples per group give the best chance of finding robust candidates, which can then be confirmed by PRM.
AdvancedCan you run TMT multiplexing?
Yes. Several samples are labelled and run together in one multiplex, with a pooled reference channel to connect multiplexes. Ratio compression, a known property of TMT, is reported.
AdvancedCan proteomics integrate with my other omics data?
Yes. Protein results can be combined with transcriptomic, metabolomic and genomic data from the same samples through our OmniIntegrate pipeline, as part of our Bioinformatics service.
AdvancedDo you support non-model organisms?
Yes, provided a protein database exists or can be built, for example from a genome or transcriptome assembly. Identification depth depends on how complete that database is.

Key literature & resources

Selected sources behind the methods and reference values on this page. Figures labelled "schematic" or "simulated" were made for this page and are not client data.

  1. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537(7620):347–355.
  2. Eliuk S, Makarov A. Evolution of Orbitrap mass spectrometry instrumentation. Annual Review of Analytical Chemistry. 2015;8:61–80.
  3. Bantscheff M, et al. Quantitative mass spectrometry in proteomics: a critical review. Analytical and Bioanalytical Chemistry. 2007;389(4):1017–1031.
  4. Bruderer R, et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Molecular & Cellular Proteomics. 2015;14(5):1400–1410.
  5. Thompson A, et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Analytical Chemistry. 2003;75(8):1895–1904.
  6. Peterson AC, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Molecular & Cellular Proteomics. 2012;11(11):1475–1488.
  7. Mertins P, et al. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Molecular & Cellular Proteomics. 2014;13(7):1690–1704.
  8. The UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Research. 2023;51(D1):D523–D531.
  9. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47.
  10. Huber W, et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics. 2002;18(Suppl 1):S96–S104.
  11. DEP: an R/Bioconductor package for differential enrichment analysis of label-free proteomics data. Bioconductor software package. bioconductor.org/packages/DEP